$TEM and $MRNA surge at the same time—AI + life sciences is worth taking another look
Tonight, the TEM intraday price once jumped to around 81, with a gain of over 14%; MRNA also climbed nearly 10% at one point, returning to around 160.
TEM trades on AI entering healthcare.
Its most valuable assets are clinical data, genomic data, and real-world healthcare data. The deeper AI penetrates the healthcare system, the higher the value of these data.
Cathie Wood actually has been betting on this direction for a long time.
During TEM’s earlier consolidation, ARK added shares multiple times—buying continuously on May 6 and May 7, and then adding again when it pulled back in July. Now TEM has already become ARKG’s third-largest holding, with a weight of about 7.81% as of September 10.
MRNA, on the other hand, is trading a different path: mRNA technology moving for real from vaccines to cancer treatments.
The personalized cancer vaccine intismeran developed in partnership between Moderna and Merck is showing positive results in Phase III melanoma trials. This is the most core basis behind MRNA’s latest repricing. Today’s continued surge is, in essence, the market reassessing whether Moderna is truly a vaccine company—or a broader personalized cancer treatment platform.
TEM handles AI + healthcare data, while MRNA handles personalized cancer treatment. With both key players seeing clear capital inflows at the same time, this signal deserves attention.
Especially since ARK has been steadily increasing its focus over the past year on genomics, AI in healthcare, and drug R&D infrastructure. Back in July this year, ARK even specifically proposed that AI is combining with genomics and multi-omics to change the healthcare economic model.
Going forward, the key is to watch whether these two leaders—TEM and MRNA—can sustain an uptrend. As long as these two leaders don’t fall behind, the likes of $RXRX.US , SDGR, ABSI, and other high-beta names can have a foundation for further expansion.
#TEM #mRNA
Tonight, the TEM intraday price once jumped to around 81, with a gain of over 14%; MRNA also climbed nearly 10% at one point, returning to around 160.
TEM trades on AI entering healthcare.
Its most valuable assets are clinical data, genomic data, and real-world healthcare data. The deeper AI penetrates the healthcare system, the higher the value of these data.
Cathie Wood actually has been betting on this direction for a long time.
During TEM’s earlier consolidation, ARK added shares multiple times—buying continuously on May 6 and May 7, and then adding again when it pulled back in July. Now TEM has already become ARKG’s third-largest holding, with a weight of about 7.81% as of September 10.
MRNA, on the other hand, is trading a different path: mRNA technology moving for real from vaccines to cancer treatments.
The personalized cancer vaccine intismeran developed in partnership between Moderna and Merck is showing positive results in Phase III melanoma trials. This is the most core basis behind MRNA’s latest repricing. Today’s continued surge is, in essence, the market reassessing whether Moderna is truly a vaccine company—or a broader personalized cancer treatment platform.
TEM handles AI + healthcare data, while MRNA handles personalized cancer treatment. With both key players seeing clear capital inflows at the same time, this signal deserves attention.
Especially since ARK has been steadily increasing its focus over the past year on genomics, AI in healthcare, and drug R&D infrastructure. Back in July this year, ARK even specifically proposed that AI is combining with genomics and multi-omics to change the healthcare economic model.
Going forward, the key is to watch whether these two leaders—TEM and MRNA—can sustain an uptrend. As long as these two leaders don’t fall behind, the likes of $RXRX.US , SDGR, ABSI, and other high-beta names can have a foundation for further expansion.
#TEM #mRNA
